Literature DB >> 21456041

Evidence for successful implementation of exposure and response prevention in a naturalistic group format for pediatric OCD.

Thomas M Olino1, Susan Gillo, David Rowe, Sean Palermo, Elizabeth C Nuhfer, Boris Birmaher, Andrew R Gilbert.   

Abstract

BACKGROUND: Although exposure and response prevention (ERP) is an effective treatment for youth with obsessive-compulsive disorder (OCD), the majority of studies, randomized clinical trials of individual therapy, find variability in treatment response. We evaluated the potential role of individual differences in OCD presentation, comorbid disorders, age, and gender on treatment effects. Moreover, we examined these potential effects in a group format in a naturalistic, clinic-based sample of patients.
METHODS: Pediatric patients with a DSM-IV diagnosis of OCD (n=41) were treated with ERP in an intensive outpatient community-based program. OCD, mood, and anxiety symptom severity was measured at baseline, during treatment, and at discharge. Trajectories and predictors of treatment outcome were measured using linear growth models.
RESULTS: We found that group-based ERP was effective in reducing pediatric OCD symptom severity in a naturalistic treatment setting irrespective of age or gender. Furthermore, ERP was found to be effective at reducing depressive symptoms but not other anxiety symptoms. We also found inter-individual variability in the discharge levels of contamination, symmetry, and intrusive sexual thoughts and in the rate of severity reduction of intrusive sexual thoughts.
CONCLUSION: Group-based ERP is an effective treatment for children and adolescents with OCD. Several factors, including symptom dimensions and comorbid psychopathology, are associated with treatment response and outcome in this pediatric population.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21456041      PMCID: PMC3207204          DOI: 10.1002/da.20789

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  20 in total

Review 1.  Scales to assess child and adolescent depression: checklists, screens, and nets.

Authors:  E J Costello; A Angold
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1988-11       Impact factor: 8.829

2.  Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity.

Authors:  L Scahill; M A Riddle; M McSwiggin-Hardin; S I Ort; R A King; W K Goodman; D Cicchetti; J F Leckman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-06       Impact factor: 8.829

3.  The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics.

Authors:  B Birmaher; S Khetarpal; D Brent; M Cully; L Balach; J Kaufman; S M Neer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-04       Impact factor: 8.829

4.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2004-10-27       Impact factor: 56.272

5.  Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.

Authors:  M F Flament; J L Rapoport; C J Berg; W Sceery; C Kilts; B Mellström; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1985-10

6.  Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder.

Authors:  Eric A Storch; Lisa J Merlo; Michael J Larson; Gary R Geffken; Heather D Lehmkuhl; Marni L Jacob; Tanya K Murphy; Wayne K Goodman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-05       Impact factor: 8.829

7.  Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.

Authors:  Angeli Landeros-Weisenberger; Michael H Bloch; Ben Kelmendi; Ryan Wegner; Jake Nudel; Philip Dombrowski; Christopher Pittenger; John H Krystal; Wayne K Goodman; James F Leckman; Vladimir Coric
Journal:  J Affect Disord       Date:  2009-07-03       Impact factor: 4.839

8.  Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder.

Authors:  Hunna J Watson; Clare S Rees
Journal:  J Child Psychol Psychiatry       Date:  2008-05       Impact factor: 8.982

9.  Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.

Authors:  Gabriele Masi; Stefania Millepiedi; Giulio Perugi; Chiara Pfanner; Stefano Berloffa; Cinzia Pari; Maria Mucci
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.

Authors:  John T Walkup; Anne Marie Albano; John Piacentini; Boris Birmaher; Scott N Compton; Joel T Sherrill; Golda S Ginsburg; Moira A Rynn; James McCracken; Bruce Waslick; Satish Iyengar; John S March; Philip C Kendall
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

View more
  5 in total

Review 1.  Hoarding in Children and Adolescents: A Review.

Authors:  Sarah H Morris; Sara R Jaffee; Geoffrey P Goodwin; Martin E Franklin
Journal:  Child Psychiatry Hum Dev       Date:  2016-10

Review 2.  Evidence base update for psychosocial treatments for pediatric obsessive-compulsive disorder.

Authors:  Jennifer Freeman; Abbe Garcia; Hannah Frank; Kristen Benito; Christine Conelea; Michael Walther; Julie Edmunds
Journal:  J Clin Child Adolesc Psychol       Date:  2013-06-09

3.  Residential treatment outcomes for adolescents with obsessive-compulsive disorder.

Authors:  Rachel C Leonard; Martin E Franklin; Chad T Wetterneck; Bradley C Riemann; H Blair Simpson; Kimberly Kinnear; Shawn P Cahill; Peter M Lake
Journal:  Psychother Res       Date:  2015-08-26

Review 4.  A review of obsessive-compulsive disorder in children and adolescents.

Authors:  Bernard Boileau
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

5.  Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive-compulsive disorder.

Authors:  M H Bloch; C A Bartley; L Zipperer; E Jakubovski; A Landeros-Weisenberger; C Pittenger; J F Leckman
Journal:  Mol Psychiatry       Date:  2014-06-10       Impact factor: 15.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.